TIBER CREEK GROUP for DAIICHI SANKYO, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340B program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Foreign entity interest: To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| COREY MALMGREN | — |
| DANIEL HOWARD ZAWITOSKI | — |
Medicare/Medicaid MMM
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Foreign entity interest: To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| COREY MALMGREN | — |
| DANIEL HOWARD ZAWITOSKI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.